<div id="readability-page-1"><p>Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) have been given an average rating of &#34;Hold&#34; by the thirteen analysts that are  covering the stock, MarketBeat Ratings reports. One research analyst  has rated the stock with a sell recommendation, six have given a hold recommendation and six have given a buy recommendation to  the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $5.5227.</p><ul><li>Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?</li></ul><p>GDRX has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft  restated a &#34;hold&#34; rating and issued a $6.00 price target on shares of GoodRx in a research report on Monday, August 11th. Wall Street Zen cut shares of GoodRx from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, November 15th. Mizuho decreased their price target on GoodRx from $5.00 to $4.00 and set a &#34;neutral&#34; rating for the company in a report on Thursday, November 6th. TD Cowen dropped their price objective on GoodRx from $7.00 to $6.00 and set a &#34;buy&#34; rating on the stock in a research note on Monday, November 10th. Finally, UBS Group decreased their target price on GoodRx from $4.25 to $4.00 and set a &#34;neutral&#34; rating for the company in a research note on Thursday, November 6th.</p><p><b>Check Out Our Latest Stock Report on GoodRx</b></p><h2>GoodRx Stock Down 1.5%</h2><ul><li>This healthcare stock making a buzz with 160% growth</li></ul><p>Shares of NASDAQ:GDRX opened at $2.71 on Friday. The firm has a market cap of $919.86 million, a P/E ratio of 30.11, a P/E/G ratio of 1.41 and a beta of 1.47. GoodRx has a 12-month low of $2.61 and a 12-month high of $5.81. The business has a fifty day simple moving average of $3.50 and a 200 day simple moving average of $4.06. The company has a quick ratio of 3.11, a current ratio of 3.11 and a debt-to-equity ratio of 0.81. </p><p>GoodRx (NASDAQ:GDRX - Get Free Report) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). GoodRx had a net margin of 3.97% and a return on equity of 9.73%. The company had revenue of $196.03 million during the quarter, compared to analyst estimates of $195.17 million. During the same period in the previous year, the company posted $0.08 EPS. The company's quarterly revenue was up .4% on a year-over-year basis.  Analysts predict that  GoodRx will post 0.13 earnings per share for the current year. </p><h2>Insider Activity at GoodRx</h2><ul><li>Gene therapy: Why does it cost millions for a single treatment? </li></ul><p>In other news, major shareholder Equity Vii L.P. Spectrum sold 23,771 shares of GoodRx stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $4.00, for a total value of $95,084.00. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. 4.53% of the stock is currently owned by company insiders. </p><h2>Institutional Investors Weigh In On GoodRx</h2><p>Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Quarry LP bought a new position in shares of  GoodRx during the 3rd quarter worth about $33,000.  Boothbay Fund Management LLC acquired a new position in  GoodRx during the 3rd quarter worth approximately $43,000.  Citizens Financial Group Inc. RI bought a new position in  GoodRx in the first quarter worth approximately $44,000.  Shay Capital LLC acquired a new stake in  GoodRx in the third quarter valued at approximately $47,000.  Finally, Jump Financial LLC acquired a new stake in  GoodRx in the first quarter valued at approximately $49,000. 63.77% of the stock is owned by institutional investors. </p><h2>About GoodRx</h2> (Get Free Report)<p>GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.</p><h2>See Also</h2><ul><li>Five stocks we like better than GoodRx</li><li>Where Do I Find 52-Week Highs and Lows?</li><li>Ulta’s Stock May Be Set for a Glow-Up—20% Upside Ahead?</li><li>What Are Growth Stocks and Investing in Them </li><li>Gates Foundation Sells MSFT Stock—Should Investors Be Worried?</li><li>Most active stocks: Dollar volume vs share volume</li><li>MarketBeat Week in Review – 12/1 - 12/5</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0RSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0RSWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in GoodRx Right Now?</h2><p>Before you consider GoodRx, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.</p><p>While GoodRx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

GDRX

<p>GoodRx Holdings, Inc. (NASDAQ:GDRX) has received a consensus "Hold" rating from thirteen analysts. The stock has mixed recommendations: one "sell," six "hold," and six "buy." The average 1-year target price is $5.5227. Recent analyst actions include Deutsche Bank's "hold" rating with a $6 target, and UBS's "neutral" rating with a $4 target. GoodRx's stock opened at $2.71, with a market cap of $919.86 million. Institutional investors own 63.77% of the stock.</p>

GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Consensus Rating of "Hold" by Analysts